Difference between revisions of "Resource:9736d9b3-fbe1-45cf-a5d0-20e19038d394"

From The Embassy of Good Science
Line 2: Line 2:
 
|Resource Type=Cases
 
|Resource Type=Cases
 
|Title=Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
 
|Title=Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
|Is About=The study by Drs X and Y and the accompanying Editorial by Drs Z and Q  regarding rofecoxib illustrate the recurring problem of discretionary or data-driven analysis<ref>FitzGerald, Garret A. "Guest authorship, mortality reporting, and integrity in rofecoxib studies." ''JAMA'' 300.8 (2008): 900-906.</ref> This is a facutal case.
+
|Is About=This is a facutal case.
 
<references />
 
<references />
|Important Because=Given the possibility of selective analysis based on observed data and the risk of positive results due to chance alone, it is critical to know in detail which analyses were prespecified and when the prespecification occurred<ref>FitzGerald, Garret A. "Guest authorship, mortality reporting, and integrity in rofecoxib studies." ''JAMA'' 300.8 (2008): 900-906.</ref>.
+
|Important Because=<br />
 
<references />
 
<references />
 
|Important For=Researchers
 
|Important For=Researchers
Line 15: Line 15:
 
}}
 
}}
 
{{Tags
 
{{Tags
|Involves=Drs Psaty; Kronmal
 
 
|Has Location=USA; United States
 
|Has Location=USA; United States
 
|Has Virtue And Value=Honesty; Reliability
 
|Has Virtue And Value=Honesty; Reliability

Revision as of 10:53, 19 October 2020

Cases

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

What is this about?

This is a facutal case.

Why is this important?


For whom is this important?

Other information

Cookies help us deliver our services. By using our services, you agree to our use of cookies.
5.1.6